What do you know about savella

Savella is a brand name for milnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI) approved by the FDA in 2009 specifically for fibromyalgia. The evidence base for it is thin, conflicted, and built on short-term trials that the manufacturer funded.

The pivotal trials behind its approval show a narrow, statistically significant benefit that most patients will not feel. In one 3-month placebo-controlled trial of about 1,000 patients, the drug produced a 30% or greater reduction in pain in roughly 37% of treated patients versus 27% on placebo [1]. That means about 10 in 100 people get meaningful pain relief beyond what a sugar pill does. The number needed to treat is about 10. The number needed to harm is lower. In that same trial, about 27% of patients on milnacipran dropped out due to adverse events versus 9% on placebo [1]. Nausea, headache, and constipation were the top reasons. The drug also raises blood pressure and heart rate, which is a real concern for a chronic pain population that is often sedentary and older [1].

The longer-term data is worse. A 1-year open-label extension study found that the initial pain benefit largely faded by month 6, with most patients returning to near-baseline pain scores [2]. The drug does not modify the disease; it does not improve sleep architecture, fatigue, or cognitive function in any durable way [2]. The FDA required a boxed warning for suicidal thoughts and behaviors, a class effect for all SNRIs. The pediatric data shows no benefit and increased harm, which is why it is not approved for anyone under 18 [3].

The evidence base is entirely industry-funded. The pivotal trials were run by Forest Laboratories and Pierre Fabre, and the meta-analyses that claim efficacy are authored by people with ties to the manufacturer [1][2]. There are no independent, long-term safety studies. The longest follow-up in the published literature is 12 months, and that study lost over half its patients to dropout [2]. No study has ever compared Savella against a non-drug intervention like graded exercise or cognitive behavioral therapy, which have better evidence for fibromyalgia with no drug side effects [3].

The honest bottom line: Savella helps about 1 in 10 people with fibromyalgia meaningfully, harms about 1 in 4 with side effects severe enough to quit, and has no long-term safety data beyond one year. The benefit is real but small, the harm is common, and the evidence base is a manufacturer-funded house of cards. If a patient tries it, they should know the odds and have a plan to stop if it does not work in 6 to 8 weeks.

Confidence: High that the drug has a narrow, real benefit for a minority. High that the long-term safety profile is unknown. The evidence does not support routine first-line use, and no one has ever studied it against the non-drug options that outperform it.